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A B S T R A C T
Background: The COVID-19 Ag (Antigen) Respi-Strip assay is a new immunochromatographic diagnostic tool
recently available for antigenic diagnosis of SARS-CoV-2. The proposed sensitivity is not higher than 60 %, but
its high specificity allows both quick decisions for the management of patients and confirmation by molecular
diagnosis for only negative tests. However, from the first tests performed, we suspected that the sensitivity
observed with routine use was much lower than that announced by the manufacturer.
Materials and methods: Over a period of one month, we compared the negative results obtained with the COVID-
19 Ag Respi-Strip kit with those obtained from qRT-PCR performed in a laboratory qualified for the molecular
diagnosis of SARS-CoV-2. All samples tested were naso-pharyngeal smears from UTM-RT medium.
Results: Of 774 patients tested, 714 negative samples were sent for confirmation, and 159 were found to be
positive by qRT-PCR. The median positive percentage agreement was 23.9 % (95 % CI: 14.2 %–38.2 %). The
Cohen’s kappa score was 0.35.
Conclusion: Using this immunochromatographic assay as a triage test did not significantly reduce the number of
samples outsourced for COVID-19 confirmation by qRT-PCR. In addition, even if the turn-around time is short,
the assay is completely manual, which is not suitable for large volumes of routine samples. The sensitivity of this
rapid test is poor, and improvements are needed to enhance its performance.
1. Introduction
Since the launch of the COVID-19 Ag Respi-Strip assay (Coris
Bioconcept, Gembloux, Belgium) upon completion of a validation study
under the National Competent Authority supervision, we en-
thusiastically implemented the company’s proposed algorithm allowing
the integration of this rapid test in the management of patients sus-
pected of COVID-19. This decision was based on the significant speci-
ficity reported (99.5 %) that allows quick decisions regarding the
management of patients. Negative results require additional examina-
tions by medical imaging and molecular detection by qRT-PCR.
We read with great interest the early April WHO advice on the use of
point-of-care immunodiagnostic tests for COVID-19 [1] as well as the
article recently published on the test validation [2] and wanted to
evaluate our current way of working.
2. Materials and methods
This prospective study was conducted over a 1-month period be-
tween April 5, 2020, and May 4, 2020, at a single 550-bed hospital site.
The beginning of this period corresponded to the epidemic peak of
COVID-19 in Belgium. Nasopharyngeal samples for the diagnosis of
COVID-19 were taken from UTM-RT swabs (Copan spa, Brescia, IT) and
sent to the laboratory. The antigenic assessment was performed using
the COVID-19 Ag Respi-Strip kit according to the manufacturer’s in-
structions. After antigenic testing was performed, the molecular as-
sessment of SARS-CoV-2 was outsourced to a university centre where it
was carried out by qRT-PCR using E-gene SARS-CoV-2 primers/probes.
3. Results
A rapid on-site verification of the performance of the COVID-19 Ag
Respi-Strip kit was carried out on 56 samples; it showed a sensitivity of
30 % (95 % CI: 16.7 %–47.9 %) a specificity of 100 %, and a positive
https://doi.org/10.1016/j.jcv.2020.104472
Received 17 May 2020; Received in revised form 22 May 2020; Accepted 25 May 2020
⁎ Corresponding author at: Department of Laboratory Medicine, Iris Hospitals South, rue Jean Paquot 63, 1050 Brussels, Belgium.
E-mail address: marie.tre-hardy@ulb.ac.be (M. Tré-Hardy).
Journal of Clinical Virology 129 (2020) 104472
1386-6532/ © 2020 Elsevier B.V. All rights reserved.
T
predictive value of 100 %, validating the decision not to confirm a
positive result. During the investigation period, 912 tests were per-
formed. Some patients were tested more than once for follow-up ac-
cording to the handling clinician’s decision. After removing duplicates,
776 patients remained for evaluation. Two tests were removed from the
statistical analysis (one non-conform and one invalid). Sixty (60) out of
774 antigenic strips were positive. Fig. 1 shows the evolution of positive
and negative molecular confirmations over the weeks as well as the
percentage of positive molecular and antigenic tests. The total number
of positive PCR samples was 159. The positive percentage agreement
during the 4 weeks ranged from 14.3 % to 34.7 % with a median of 23.9
% (95 % CI: 14.2 %–38.2 %). The Cohen’s kappa score was 0.35.
4. Discussion
Under routine conditions, the sensitivity of the antigen detection of
SARS-CoV-2 with the immunochromatographic COVID-19 Ag Respi-
Strip kit was significantly lower than that announced by the manu-
facturer or reported by Vandenberg [2], although we limited ourselves
to using qRT-PCR as the comparison method. In our series, we observed
a median sensitivity of 23.9 %. Moreover, compared with the expected
performance, the poor observed sensitivity gave rise to 80 % more false
negative samples and 2.2 times fewer positive samples answered on
site.
Some authors reported a sensitivity of similar molecular methods
close to 70 % [3]. To obtain a better understanding of the actual sen-
sitivity, we used the patient database constructed for a serological
evaluation for which approval was obtained from our Ethics Committee
[4]. When combining molecular diagnosis, chest CT scans and sugges-
tive clinical patterns of COVID-19, we observed that PCR was positive
in only 199 patients among the 236 patients (76.2 %) with suggestive
symptoms of COVID-19 or a positive chest CT. These results are in line
with the previously published false negative rate of approximately 20 %
for qRT-PCR [5–7].
As mentioned in the WHO advice [1], the performances of antigenic
tests depend on several factors, such as the time from onset of illness,
the specimen viral content, and other preanalytical and analytical
considerations, as has been previously reported for other respiratory
viruses. The WHO estimates that at least half of COVID-19-infected
patients might be missed by such tests and therefore does not currently
recommend their use. Vandenberg calculated their performance based
on a threshold cycle (Ct) below 22 [2]. In the meantime, a notice from
the manufacturer signalled that some hospitals observed negative re-
sults with a Ct of 13.45 or positive results with a Ct higher than 33,
underlining the unclear relationship between protein and RNA
detection. The main limitation of our investigation was our inability to
match our results against the Ct of the molecular analyses since these
were outsourced. We also focused on the sensitivity of the test. How-
ever, specificity did not appear to be a priority, given that the high
prevalence of disease amplifies positive predictive value of the test
when it is are prescribed for patients in a COVID-19-compatible clinic.
5. Conclusion
Our routine results demonstrate that the concordance between an-
tigenic and molecular testing is fair regarding the kappa score [8] and
that this rapid assay does not reduce costs per patient. A thorough
validation in appropriate populations and settings should have been
performed by the manufacturer before a large-scale implementation.
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Fig. 1. Evolution of the number of positive and negative PCRs among samples
sent for confirmation of negative antigenic testing and the percentage of posi-
tive PCRs (solid line) and antigenic testing (dashed line) during the 4 weeks of
observation.
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